Clinical Trial Update: Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy, pharmacokinetics, safety, and tolerability of IGSC 20% in subjects with primary immunodeficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• IGSC 20% (immunoglobulin G 20%)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Primary Immunodeficiency | Phase 3 | Status: COMPLETED | Results posted: 2020-06-16